SaaS companies scale revenue not by adjusting price points, but by creating distinct packages for different segments. The same core software can be sold for vastly different amounts to enterprise versus mid-market clients by packaging features, services, and support to match their perceived value and needs.

Lilly’s next-generation obesity drug shows unprecedented weight loss but with a harsher side effect profile. This suggests a market segmentation strategy targeting the most severely obese patients, rather than competing directly with existing therapies for the broader population. The market is evolving beyond a simple race for maximum efficacy.

The two pharma giants are competing aggressively in the direct-to-consumer channel. They're cutting prices on their GLP-1 drugs, anticipating that lower costs will drive significantly higher volume and sales in the long run, even if it hurts short-term revenue forecasts.

Tirzepatide is a rare "once in a blue moon" drug because it is both more potent and better tolerated than its main competitor. This paradoxical profile—achieving superior efficacy with fewer side effects—has established it as the "king of the hill" in the obesity market and created an extremely high bar for any challenger.

Eli Lilly is leveraging its massive GLP-1 drug revenue for a long-term strategic play. Instead of just acquiring single assets, the company is investing in global innovation hubs, supercomputing with NVIDIA, and incubators to build a sustainable innovation backbone, aiming to avoid typical patent cliff-driven downturns.

To commercialize curative 'one-and-done' genetic medicines, Eli Lilly is considering a subscription-like model. The procedure could be free upfront, with patients or insurers paying an ongoing fee only as long as it works.

The obesity drug market is seeing prices cut in half much faster than anticipated, despite being a duopoly. This rapid price degradation is driven by Novo Nordisk, the market laggard, aggressively using price as a weapon to reclaim market share from Eli Lilly, a dynamic typically seen only after multiple new players enter.

Lilly's next-generation "triple G" drug, Retratrutide, is not designed to replace its blockbuster Tirzepatide. Due to its "ultra potent" nature and less favorable side effect profile, it will be strategically positioned for a specific subset of patients with very high BMIs (e.g., 40+) who require maximum weight loss.

Eli Lilly's $3.25B acquisition of Colonia is a strategic move to secure future revenue. The company is leveraging massive profits from obesity drugs to buy a potential blockbuster franchise, proactively addressing the eventual patent cliff on its current bestsellers.